Top 50 Health Care VC Funds & Investors in Denmark (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
32 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $8M–$125M |
|
BioInnovation Institute
VC Fund
|
18 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $516k–$5.2M |
|
Vaekstfonden
VC Fund
|
18 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $440k–$4.6M |
|
PSV
VC Fund
|
15 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $88k–$4.6M |
|
Export and Investment Fund
VC Fund
|
15 | Denmark, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Health Care | $395k–$84M |
|
Seed Capital
VC Fund
|
13 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $515k–$17M |
|
Sunstone Life Science Ventures
VC Fund
|
7 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
People Ventures
VC Fund
|
7 | Denmark, Sweden, United States | Seed, Pre-Seed, Series A | Software, Health Care, Internet of Things | $1.1M–$21M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
West Hill Capital
VC Fund
|
6 | United Kingdom, Denmark, Germany | Series A, Seed | Software, Health Care, Financial Services | $1.8M–$15M |
|
Gilde Healthcare
VC Fund
|
5 | United States, The Netherlands, Germany | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $8.8M–$120M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, SaaS, Biotechnology | $1.2M–$22M |
|
Delphinus Venture Capital
VC Fund
|
4 | Denmark | Seed, Pre-Seed, Series A | Health Care, Food and Beverage, Hospital | $1.7M–$3.4M |
|
RA Capital Management
VC Fund
|
4 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $27M–$230M |
|
Innovation Fund Denmark
VC Fund
|
4 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $22k–$1.6M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$88M |
|
Innovestor
VC Fund
|
4 | Finland, Denmark, Sweden | Seed, Pre-Seed | Software, Health Care, Information Technology | $163k–$4.1M |
|
Crowberry Capital
VC Fund
|
3 | Iceland, Denmark, Finland | Seed, Series A, Pre-Seed | Software, Gaming, Health Care | $1k–$17M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
Forbion Capital Partners
VC Fund
|
3 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $12M–$176M |
|
byFounders
VC Fund
|
3 | Denmark, United States, Sweden | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Health Care | $800k–$64M |
|
Sweet Capital
VC Fund
|
3 | United States, United Kingdom, Israel | Seed, Series A | Apps, Software, Mobile | $1.8M–$32M |
|
Crista Galli Ventures
VC Fund
|
3 | United Kingdom, United States, Sweden | Seed, Pre-Seed, Series A | Health Care, Medical, Wellness | $655k–$14M |
|
EIR Ventures
VC Fund
|
3 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Pre-Seed, Seed | Software, Information Technology, Artificial Intelligence | $876k–$4.2M |
|
DSM Venturing
VC Fund
|
3 | United States, Canada, Israel | Series A, Series B | Biotechnology, Health Care, Manufacturing | $3.5M–$32M |
|
Ysios Capital
VC Fund
|
3 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$135M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Antler
VC Fund
|
3 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $100k–$29M |
|
CBC Investment Group
VC Fund
|
2 | Sweden, Denmark, Germany | Seed, Series B | Software, Biotechnology, SaaS | |
|
Digital Health Ventures
VC Fund
|
2 | Germany, Denmark, France | Seed, Series A, Series B | Health Care, Fitness, Wellness | $2.2M–$12M |
|
VentureFriends
VC Fund
|
2 | Greece, United Kingdom, United States | Seed, Series A, Pre-Seed | FinTech, Software, E-Commerce | $105k–$25M |
|
Johnson & Johnson Development Corporation
VC Fund
|
2 | United States, United Kingdom, Canada | Series C, Series B | Health Care, Biotechnology, Medical | $12M–$49M |
|
Investo Capital
VC Fund
|
2 | Denmark | Seed | Health Diagnostics, Computer, Software | $1.6M–$3.4M |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$115M |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Wellcome Trust
VC Fund
|
2 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.3M–$127M |
|
Lundbeckfonden Ventures
VC Fund
|
2 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$95M |
|
Karolinska
VC Fund
|
2 | Sweden, Denmark, United States | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $1.3M–$73M |
|
NOON Ventures
VC Fund
|
2 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | |
|
CAPNOVA
VC Fund
|
2 | Denmark, United States, India | Seed, Pre-Seed | Software, Information Technology, B2B | $147k–$2.4M |
|
Chr. Augustinus Fabrikker
VC Fund
|
2 | Denmark | Series B, Series A, Series C | Software, Audio, Video | $16M–$170M |
|
14W
VC Fund
|
2 | United States, United Kingdom, Spain | Seed, Series A, Series B | E-Commerce, Fashion, Health Care | $1.1M–$40M |
|
Wellington Partners
VC Fund
|
2 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3.1M–$55M |
|
Inventure
VC Fund
|
2 | Finland, Sweden, United States | Seed, Series A, Series B | Software, Information Technology, Health Care | $549k–$23M |
|
Balderton Capital
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, Financial Services, Artificial Intelligence | $4.5M–$99M |
|
Dawn Biopharma
VC Fund
|
2 | Denmark, France, Belgium | Seed, Series A, Series B | Biotechnology, Health Care, Therapeutics | |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | |
|
Inkef
VC Fund
|
2 | The Netherlands, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2.2M–$88M |
|
Acorn Venture Fund
VC Fund
|
2 | Denmark | Seed | Health Care | |
| Access all 216 VC funds in Denmark Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 314
- Round size: Series A $8M–$100M; Series B $12M–$125M; Series C $30M–$115M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Tobira Therapeutics — Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 72
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
- Lead/follow: 90% lead, 10% follow
Portfolio highlights
- Zeta Diagnostics — First-in-class hardware-and-software-as-a-service diagnostics for the 400M suffering from middle ear problems
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 196
- Round size: Seed $810k–$4.6M; Pre-Seed $440k–$1.2M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Captego — Unique, high-speed field data capture. Empower your inspectors & surveyors with our unique collection app. Benefit from high quality data to automate reports and data insights.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 136
- Round size: Seed $500k–$4.6M; Pre-Seed $88k–$2.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $42M in 2020
Portfolio highlights
- Jabbr — Jabbr allows to capture boxing matches with a virtual video production.Its goal is to make video production and advanced performance analytics in combat sports available to anyone with a smartphone.
- Thiax — ThiaX maps the strain and crystallinity in polymer and composite materials using cutting-edge X-ray diffraction (XRD) technology.
- Enerin — Enerin reduces energy consumption and costs through our know-how within energy technology and operation of heating and cooling systems, including industrial heat pumps through our products Thermonitor, HoegTemp, WaveClean, Feedwater systems and Niprox water treatment.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 101
- Round size: Seed $395k–$11M; Series A $3.8M–$84M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Akson Robotics — Akson Robotics is a developer of AI and robotics-based products that focus on greener and efficient agriculture through precision farming.
- Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
- Coalescent Mobile Robotics — Coalescent Mobile Robotics is a robotics company developing mobile robots to automate transportation processes in the mutilple industries.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 180
- Round size: Seed $515k–$4.9M; Series A $3.5M–$17M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $73M in 2021
Portfolio highlights
- Cardlay — Build your own white-label card and expense management solution with Cardlay. Our platform helps banks, fleets, and tech partners launch modern spend management solutions fast.
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Templafy — Templafy automates documents to remove risk and increase efficiency for over 800 organizations around the world.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 55
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 15% lead, 85% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Backing founders with people, money and presence | People Ventures
Show more...Investment focus
- Industry: Software, Health Care, Internet of Things
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 29
- Round size: Seed $1.1M–$19M; Pre-Seed $1.5M–$1.6M; Series A $6.3M–$21M
- Lead/follow: 62% lead, 38% follow
Portfolio highlights
- Opally — The aim of Opally is to assist hospitality professionals in spending more time crafting exceptional guest experiences and less time on emails.
- Hosted·AI — Hosted·AI is a software company that offers GPUaaS orchestration, AI tools, and cloud infrastructure solutions.
- Pandektes — Legal Research, redefined.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 8
- Round size: Seed $1.2M–$3.9M; Series A $4.8M–$5.9M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 57
- Round size: Seed $2.6M–$5.9M; Series A $1.8M–$15M
- Lead/follow: 84% lead, 16% follow
Portfolio highlights
- Algiecel — ALGIECEL - Securing CO2 neutrality with carbon capture as a service Microalgae Cultivation – Easily scalable with modular photobioreactorsALGIECEL is transforming CO2 emissions and LED light into microalgae biomass and Oxygen. The company has developed a plug & play photobioreactor that can be stacked and packed as it is fitting intostandard shipping containers. The reactor is easily installable and requires little technical know-how from small and mid-size industrial clients.ALGIECEL has designed a novel business model that transforms the cost challenge of CO2 removal into a profitable business opportunity across the entire value chain through revenue sharing from the microalgae biomass and carbon credit sales.ALGIECEL´s primary target markets for the application of the photobioreactor will be the biogas and fermentation sectors. In these fast-growing industries many sites are too small for large power-to-x projects to reduce CO2 emissions. Here, ALGIECEL aspires to help in solving the CO2 challenge with our modular carbon capture technology and revenue sharing business model.
- Cercare Medical — Cercare Medical designs and develops a software tool for supporting acute stroke management, helping clinicians to evaluate the effect of a stroke. The software draws up the infarct-area within 30 seconds, locate perfusion area from images within 30 seconds and evaluate mismatch and generate a volume number of salvageable tissue. Cercare Medicalwas incorporated in 2013 under the name Combat Stroke and is based in Denmark.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 124
- Round size: Series A $8.8M–$63M; Series B $15M–$120M; Series C $21M–$75M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- ProVerum Medical — The ProVee stent from Proverum Medical uses 3-D geometry which mirrors and engages with the anatomy of the prostate. The system alleviates Lower Urinary Tract Symptoms (LUTS) by opening the prostatic urethra, applying radial force to the prostatic lobes.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 29
- Round size: Seed $1.2M–$9.1M; Series A $5.6M–$22M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Tame — ABOUT With Tame you can fully customise your virtual events, and make them fun, engaging & exciting to attend.- Apply your branding: Customise your virtual event completely - Personalised Welcome: Personal welcome message when attendees enter - Multiple stages: Broadcast content across multiple stages. - Live streaming: Stream live via anybroadcasting software - Pre-recorded videos: Broadcast pre-recorded videos as if it was live - Breakout sessions: Enable public or private breakout sessions. - Virtual Sponsor booths: Allow attendees to engage with sponsors live. - Customise Chat: Allow for 1:1 chat, group chat or session chat. - 1:1 Video Meetings: Empower social networking virtually.OUR COMPANY We are an experience-centric company, and we believe in the power of great experiences. Our international group of dreamers, creators and rule-breakers passionate about merging design and technology together, enables us to transform that into one truly amazing event platform.OUR PEOPLE The team behind Tame has an aggregated decades long experience of creating events and building products that solve real problems for real people. So, what got us here? Our ambition to change a broken event industry through innovation, customer obsession and a relentless focus on the great experience.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Delphinus Venture Capital is a venture investment management firm.
Show more...Investment focus
- Industry: Health Care, Food and Beverage, Hospital
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 9
- Round size: Seed $1.7M–$3.4M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Alcolase — Alcolase is a danish startup who develops the world's first enzyme system breaking down alcohol in the stomach (before it enters the blood).
- Decameal — Decameal envisions future food systems that are stable and sustainable, as well as healthy marine habitats.
- Ardos — Ardos is a developer of radiotherapy software designed to enhance cancer treatment.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 425
- Round size: Series B $27M–$152M; Series C $40M–$200M; Post-IPO Equity $30M–$230M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
- Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
- ILiAD Biotechnologies —
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 87
- Round size: Seed $66k–$1.3M; Grant $22k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Prezio — Prezio is an electricity tariff data API for Europe. We aggregate, structure, and serve real-time and historical electricity pricing data - spot prices, retail tariffs, and grid fees - so energy applications don't have to build and maintain that data infrastructure themselves. Typical customers are developers and product teams building EVsmart charging, heat pump control, home batteries, and solar optimization tools - anything that needs to know what electricity actually costs, right now or over time, across European markets.
- ENZIDIA — We crack the fundamental bottlenecks of enzyme engineering with unprecedented screening and data collection capacity
- Cacto Health — Cacto Health is the Developer of a medical device system designed for monitoring lymphedema in breast cancer patients.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 121
- Round size: Series A $5.7M–$55M; Series B $14M–$88M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 74
- Round size: Seed $507k–$4.1M; Pre-Seed $163k–$2M
- Lead/follow: 62% lead, 38% follow
- Last fund: May invest from a new fund soon — raised $35M in 2020
Portfolio highlights
- Bahn Express — Bahn Express is a global car transportation company that supports independent contractors while offering quick and easy auto shipping throughout Europe.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Neumirna Therapeutics — Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions.
Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more...Investment focus
- Industry: Software, Gaming, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Iceland, Denmark, Finland
Investor stats
- Total investments: 45
- Round size: Seed $1.6M–$4.7M; Pre-Seed $1k–$1.3M; Series A $5.7M–$17M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Quanscient — We are building next generation simulation software-as-a-service utilizing Quantum computing algorithms. Our specialty domain of simulations is Computational Electromagnetics.
- Hemi Health — Hemi Health is a Danish digital-first headache and migraine clinic specializing in diagnosis, personalized treatment, and care for headaches using technology like an app for symptom tracking and video consultations.
- Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 171
- Round size: Series A $14M–$176M; Series B $12M–$155M; Series C $12M–$113M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, United States, Sweden
Investor stats
- Total investments: 98
- Round size: Seed $1.5M–$7.6M; Pre-Seed $800k–$4.2M; Series A $6.1M–$64M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — raised $117M in 2021
Portfolio highlights
- Flare — Flare builds infrastructure for a more internet by connecting real-world data with machine learning in a verifiable way.This combines human intelligence with advanced AI to improve the clarity and reliability of information.Its goal is to create a shared, high-quality knowledge foundation that helps people navigate information with confidence.
- DataCrunch.io — DataCrunch is a cloud service provider which facilitates utilization and integration of state of the art AI/ML models
- Spiral Hydrogen — Spiral Hydrogen's mission is to lower the price of green hydrogen below that of fossil hydrogen, so opening up an industry for decarbonization and making hydrogen transportation and heating commercially viable.
Sweet Capital is the private investment fund of the founders of King.com (Candy Crush Saga), following their $5.9b sale to Activision Blizzard in 2015 (ATVI:US; acq. MSFT:US).
Show more...Investment focus
- Industry: Apps, Software, Mobile
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 63
- Round size: Seed $1.8M–$5M; Series A $3M–$32M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Wellthy — Wellthy is a family care concierge service bringing relief to families managing complex or ongoing care situations. The company's solution brings relief to families managing aging-related concerns, childcare, special needs, health conditions, and other complex or ongoing care situations. Wellthy connects families with a dedicated CareCoordinator to help tackle the logistical and administrative tasks of caring for the ones they love, including themselves.Through Wellthy’s online platform, families can keep track of appointments, save contacts, organize tasks by type, store important documents, and revisit past conversations.The company was founded in 2014 by Lindsay Jurist-Rosner and Kevin Roche and is headquartered in New York, United States.
- Aula Education — Aula's created by educators to make every learning experience truly engaging. See how our simple, social platform can transform your digital learning environment.
- Immersive Gamebox — Electric Gamebox delivers immersive team Adventures in the world's smartest room. Our GameBox Adventure pods combine projection mapping, touch screen, motion tracking and surround sound technologies to create an entirely new form of digital group entertainment.
Physician-led venture capital investing in TechBio, DeepTech Healthcare, and Digital Health.
Show more...Investment focus
- Industry: Health Care, Medical, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Sweden
Investor stats
- Total investments: 36
- Round size: Seed $960k–$8.5M; Pre-Seed $655k–$2.5M; Series A $5.2M–$14M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Jude — Science-backed food supplement that makes you feel empowered, not embarrassed.
- Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
- Collective Minds Radiology — Collective Minds develops and delivers a cloud-based collaboration platform for healthcare and research with access to data, human and digital expertise.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Series A $20M–$73M
- Lead/follow: 58% lead, 42% follow
- Last fund: Likely still investing — raised $143M in 2021
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- Synklino — Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Pre-Seed, Seed
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 16
- Round size: Seed $876k–$4.2M; Pre-Seed $917k–$1.7M
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- Eupry — Be in full control of your temperature compliance at all times. Collect temperature monitoring, mapping, and calibration in one GxP-compliant solution.
- Juristic — Juristic is the world's most advanced legal visualising tool - and it can automate legal drafting too! Solve complex legal and financial matters in real time. We are developing next-generation tools for advisers.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 90
- Round size: Series A $3.5M–$32M; Series B $4.1M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 78
- Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Prexton Therapeutics — Voici la page d'accueil du site web
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$21M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Commit Biologics — Add a description for facebook
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 935
- Round size: Seed $362k–$5.8M; Pre-Seed $100k–$1.3M; Series A $4.6M–$29M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Gyodi —
- Pathzero — Pathzero's carbon management platform enables any business to start disclosing corporate carbon emissions and the actions being taken to address them.
- Unseen — Unseen is a market intelligence platform for commercial real estate.
CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series B
- Geography: Sweden, Denmark, Germany
Investor stats
- Total investments: 12
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
- Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
- Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Digital Health Ventures (DHV) is a sector-focused Venture Capital Fund based in Berlin. They are experienced early-stage investors with a track record that includes several strong European healthcare innovators. Our mission is to build a sustainable Digital Health ecosystem. They actively support portfolio entrepreneurs and leverage our networks intech and healthcare. They work together closely and find joint solutions. They invest in startups which will play a significant role in healthcare and that want a strong partner during this journey.
Show more...Investment focus
- Industry: Health Care, Fitness, Wellness
- Stage:Seed, Series A, Series B
- Geography: Germany, Denmark, France
Investor stats
- Total investments: 9
- Round size: Seed $2.2M–$2.5M; Series A $9M–$12M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Wefight — Wefight is an open door for patients treated outside clinical settings. It makes it possible to offer services and facilitates the collect of data in real life. Our goal: to secure patients at home and save time for care teams.
- TeleClinic — TeleClinic's vision is to provide everyone with a full first-stop-shop for all health related questions. First and foremost, this means guaranteeing first-class medical care at all times. They want to do that with the help of digital possibilities and they work on that every day.
- Handl Health — Making healthcare price transparency simple, insightful and actionable.
VentureFriends is a venture capital fund that invests in tech-enabled companies. VentureFriends (VF) is a venture capital fund specialising in seed stage startups. VF seeks to invest in tech-enabled B2C and B2B startups that can develop a sustainable moat over time and have a sweet spot for PropTech, FinTech, Marketplaces, and SaaS. The fundtypically invests between €0.3M - €2.5M and can follow on up to a total of €5 - 10M. VentureFriends invests predominantly in Europe and is founded by ex-entrepreneurs and angel investors, thus having an entrepreneurial and founder-friendly philosophy.
Show more...Investment focus
- Industry: FinTech, Software, E-Commerce
- Stage:Seed, Series A, Pre-Seed
- Geography: Greece, United Kingdom, United States
Investor stats
- Total investments: 120
- Round size: Seed $424k–$6.7M; Pre-Seed $105k–$3.4M; Series A $2.7M–$25M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $110M in 2021
Portfolio highlights
- BibeCoffee — BibeCoffee is an IoT real-time monitoring solution that transforms every professional coffee machine to a smart connected terminal minimizing revenue Loss and safeguarding brand quality image
- Spotawheel — Spotawheel is a trusted high-tech used cars B2C platform that redesigns the whole buy-sell process from scratch, ensuring value, transparency and customer satisfaction at the highest levels throughout.
- Cube AI — Cube AI provides software that applies machine learning to business workflows and data. The platform enables creation of AI assistants, connections to internal data sources, and task automation through APIs and integrations. Capabilities include natural language processing for classification, summarization, and question answering, retrieval overdocuments and knowledge bases, and analytics that surface insights from structured and unstructured data. Solutions cover use cases such as customer support, sales enablement, lead routing, and document processing, helping teams reduce manual steps and standardize processes. Tooling includes SDKs, dashboards, and monitoring to deploy, observe, and refine models in production.
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series C, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 129
- Round size: Series B $15M–$49M; Series C $12M–$40M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Prana Thoracic — A minimally invasive, lung-sparing device that will provide physicians and patients with the certainty they need to move forward with treatment.
- Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
- Osteal Therapeutics — Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
Investo Capital is a Danish venture capital firm based in Aalborg. They invest in carefully selected Danish early-growth companies within tech business areas in the broad sense. The target group is innovative companies with proof of business, strategic thinking, and strong growth prospects in Denmark. Strategic corporate concepts and competentmanagement are essential features. The investment focus is Technology, IT, SAAS- and med-tech.
Show more...Investment focus
- Industry: Health Diagnostics, Computer, Software
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 4
- Round size: Seed $1.6M–$3.4M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Tentoma — Professional packaging machines. Horizontal stretch film packaging machines and innovative industrial wrapping and packaging equipment.
- Create it REAL — Tailored 3D printing solutions. We help you to get and control material, software, and 3D printers to start a 3D printed production unit.
- Brainreader — Brainreader was founded in 2011 as a spin-off from Aarhus University by a team of highly skilled and motivated individuals with complementary competencies dedicated to bringing our brain image analysis technology to the clinical market.Research done by The European Medicines Agency’s shows, that baseline measurement of low hippocampalvolume (i.e., atrophy) is a supportive indicator of evolution from cognitive impairment to Alzheimer´s disease and dementia. The Brainreader software is developed on the basis of such research.Brainreader wants to be a dominant player in the market for structural analysis of MRI’s. We want Neuroreader™ to be the routine tool of choice for physicians and MRI clinics all over the world when assessing structural MRI’s.Brainreader is currently bringing our new cutting-edge software tool, Neuroreader™, to the clinical market. It is our vision that Brainreader will deliver objective, precise, and personal analysis of brain scans. Ultimately increasing quality of life for the patient and significantly reducing disease-related costs for society.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 182
- Round size: Series A $3.7M–$87M; Series B $15M–$114M; Series C $22M–$115M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
- Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 163
- Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 115
- Round size: Grant $1.3M–$8M; Series C $10M–$127M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Cultivarium — We develop molecular, hardware and software tools to accelerate the adoption of microbes for beneficial biotechnologies.
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 65
- Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $16M–$53M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- Notify Therapeutics — Notify Therapeutics develops therapies for the treatment of infertility. By targeting the early and hormone-independent phase of egg maturation, the company aims at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy. It utilizes drug-inducing factors that regulate the intracellular AKTpathway and target the early and hormone-independent phase of egg maturation for the treatment.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 26
- Round size: Series A $1.3M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
- BOOST Pharma — Boost Pharma: Developing a stem cell therapy for Osteogenesis Imperfecta.
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more...Investment focus
- Industry: Software, Information Technology, B2B
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, India
Investor stats
- Total investments: 24
- Round size: Seed $147k–$2.4M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
- Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
- ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
Chr. Augustinus Fabrikker operates as an investment management firm with a core focus on dedicated ownership of Danish businesses. Founded in 1750, Chr. Augustinus Fabrikker has a capital base of more than 30 billion, a significant player in the Danish business community. It is owned by the Augustinus Foundation, which is one of Denmark'slargest cultural foundations, and also makes significant contributions to research and social initiatives.
Show more...Investment focus
- Industry: Software, Audio, Video
- Stage:Series B, Series A, Series C
- Geography: Denmark
Investor stats
- Total investments: 15
- Round size: Series A $16M–$170M; Series B $21M–$76M; Series C $44M–$82M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
- Eupry — Be in full control of your temperature compliance at all times. Collect temperature monitoring, mapping, and calibration in one GxP-compliant solution.
- Podimo — Podimoa is an open podcast platform that offers a subscription service for creators. Founded in 2019, Podimo is a podcast and short-form audio platform which offers personalized recommendations to listeners, while offering creators a share of revenue via premium subscriptions. Co-founded by Morten Strunge, Nikolaj Koppel, Andreas Sachse, EvaLægdsgaard, and Sverre Dueholm, Podimo is hoping to capitalize on the rise in consumption in podcasts.
14W is a Venture Capital firm based in New York, focusing on the intersection of technology and consumer behaviour.
Show more...Investment focus
- Industry: E-Commerce, Fashion, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Spain
Investor stats
- Total investments: 87
- Round size: Seed $1.1M–$14M; Series A $5M–$14M; Series B $12M–$40M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Exoticca — Exoticca develops an online platform intended to facilitate travel booking. The company's platform offers holiday packages which includes flights, accommodation, meals, guides and private transports, for exotic locations all around the world, enabling travelers to book travel packages online at competitive prices.
- Cayena — Cayena is a B2B marketplace for the $100b+ wholesale food industry in Latin America. The company allows restaurants, bars, bakeries, hotels and dark kitchens to procure their inventory from multiple suppliers with next day delivery and a comprehensive suite of add-on services.
- Power Life Science — Discover cutting-edge therapies by enrolling in clinical trials. Power helps patients everywhere take control of their care.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 193
- Round size: Series A $3.1M–$33M; Series B $6.7M–$55M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $222M in 2019
Portfolio highlights
- nyra health — myReha is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. myReha was founded in 2020 and was headquartered in Vienna, Austria.
- UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
- Heliatek — As the technology leader in organic photovoltaics, Heliatek develops, produces and distributes industrial-grade organic PV solar solutions for virtually any building surface (horizontal, vertical, curved, rigid, and flexible). Heliatek stands for energy solutions designed for various traditional and never been possible before applications based onits unique features – it is ultra-light, flexible and truly green. HeliaSol® is a ready-to-use solution, ideal for retrofitting on existing building structures. HeliaFilm® is tailor-made solar film for companies in the building and construction material industry, to integrate into their façade or roof system products. Heliatek currently employs about 160 people at the Dresden and Ulm locations in Germany.The Free State of Saxony, the Federal Republic of Germany, and the European Union funded research and development, as well as the installation of the production technology.
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Finland, Sweden, United States
Investor stats
- Total investments: 164
- Round size: Seed $549k–$6M; Series A $1.3M–$17M; Series B $1.3M–$23M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $169M in 2022
Portfolio highlights
- Omocom — Omocom offers safe, simple and secure insurance for all kind of renting, sharing and re-using, digitally, automated and integrated into the sales flow of the platform
- Moncyte Health — Unique technology and novel data for personalized and optimal treatment of high cholesterol
- Blueprint Genetics — We offer complete genetic testing and genetic diagnostics to medical professionals worldwide. Learn more about our winning clinical-grade NGS offering!
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, Financial Services, Artificial Intelligence
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 377
- Round size: Series A $4.5M–$30M; Series B $9.3M–$85M; Series C $12M–$99M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely actively investing — fresh fund, raised $615M in 2024
Portfolio highlights
- 32Co — Collaborate on treatments with the UK's top orthodontists using advanced aligner materials.
- GoCardless — GoCardless is the global leader in recurring payments. GoCardless' global payments network and technology platform take the pain out of getting paid for businesses with recurring revenue. More than 40,000 businesses worldwide, from multinational corporations to SMBs, transact through GoCardless each month, and the business processes $10bn ofpayments each year. GoCardless now has four offices in the UK, France, Australia, and Germany.
- Wayve — Wayve are pioneering an AI-centric approach to self-driving, inspired by our vision of a smarter, safer and more sustainable world.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A, Series B
- Geography: Denmark, France, Belgium
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Bambusa Therapeutics — Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 18
- Lead/follow: no public data
Portfolio highlights
- Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Avantium — Build a sustainable future with Avantium. Leading the change in green chemistry and innovative solutions.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Germany
Investor stats
- Total investments: 83
- Round size: Seed $2.8M–$21M; Series A $3.2M–$42M; Series B $2.2M–$88M
- Lead/follow: 52% lead, 48% follow
- Last fund: May invest from a new fund soon — raised $585M in 2016
Portfolio highlights
- NMD Pharma — NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
- Comet Therapeutics — DropCatch.com helps you secure expiring domain names.
- Cardior Pharmaceuticals — Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.
Venture Capital
Show more...Investment focus
- Industry: Health Care
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Healper — An online matching platform where you get matched with the mental health tools and psychologist who fits your personality, demography, and personal factors, giving you the best chance for effective therapy. The platform includes an online survey, psychologist profiles, booking and payment systems, reminders, sessions, and feedback systems. Webelieve better mental health starts with having a therapist in whom you trust, have chemistry with, and have relevant expertise. Healper will make a better match between you and the therapist based on professional and personal factors through a safe and smooth user journey. We believe a better match means better therapy, empowering you to get more out of your life.
Health Care VC funding in Denmark at a glance
Stats across 224 deals from 216 investors.
Access all 216 VC funds in Denmark Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care VC Funds in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 216 VC funds investing in Denmark Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!